Literature DB >> 27096536

Yin and yang of 4E-BP1 in cancer.

Ren Wang1, Shridar Ganesan2, X F Steven Zheng2.   

Abstract

Entities:  

Keywords:  4E-BP1; cancer; kinase; mTOR; translation

Mesh：

Substances：

Year:  2016        PMID： 27096536      PMCID： PMC4934074          DOI： 10.1080/15384101.2016.1168200

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  Targeting mammalian target of rapamycin (mTOR) for health and diseases.

Authors:  Chi Kwan Tsang; Haiyan Qi; Leroy F Liu; X F Steven Zheng
Journal:  Drug Discov Today       Date:  2006-12-15       Impact factor: 7.851

Review 2.  4E-BP1, a multifactor regulated multifunctional protein.

Authors:  Xiaoyu Qin; Bin Jiang; Yanjie Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

Authors:  Yanjie Zhang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 4.  Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.

Authors:  Yan-Jie Zhang; Yanwen Duan; X F Steven Zheng
Journal:  Drug Discov Today       Date:  2011-02-17       Impact factor: 7.851

5.  A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.

Authors:  Steve Braunstein; Ksenia Karpisheva; Carolina Pola; Judith Goldberg; Tsivia Hochman; Herman Yee; Joan Cangiarella; Rezina Arju; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell       Date:  2007-11-09       Impact factor: 17.970

Review 6.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

7.  Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers.

Authors:  Erhan Bilal; Kristen Vassallo; Deborah Toppmeyer; Nicola Barnard; Inga H Rye; Vanessa Almendro; Hege Russnes; Anne-Lise Børresen-Dale; Arnold J Levine; Gyan Bhanot; Shridar Ganesan
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240
  7 in total
  6 in total

1.  The impact of exogenous CO releasing molecule CORM-2 on inflammation and signaling of orthotopic lung cancer.

Authors:  Li Shao; Congyang Liu; Shuhua Wang; Jiannan Liu; Li Wang; Liping Lv; Yong Zou
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

2.  Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model.

Authors:  Doerte Poburski; Christiane Leovsky; Josefine Barbara Boerner; Luisa Szimmtenings; Michael Ristow; Michael Glei; René Thierbach
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

3.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

Review 4.  PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.

Authors:  Alia Ghoneum; Neveen Said
Journal:  Cancers (Basel)       Date:  2019-07-05       Impact factor: 6.639

Review 5.  Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation.

Authors:  Dawid Przystupski; Marek Ussowicz
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

6.  Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells.

Authors:  Ragnhild Haugse; Anika Langer; Elisa Thodesen Murvold; Daniela Elena Costea; Bjørn Tore Gjertsen; Odd Helge Gilja; Spiros Kotopoulis; Gorka Ruiz de Garibay; Emmet McCormack
Journal:  Pharmaceutics       Date:  2020-11-06       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.